| IV-01 Nikolaos Alimpertis Revising the assessment of bioequivalence in the light of finite absorption time (FAT) concept: The axitinib case Thursday 15:00-16:30 |
| IV-02 Rami Ayoun Alsoud Model-based Allometric Scaling Approaches for Predicting Human Pharmacokinetics of CB 4332, a Therapeutic Complement Factor I Protein Thursday 15:00-16:30 |
| IV-03 Geraldine Celliere A novel model-integrated design for bioequivalence of long acting injectables Thursday 15:00-16:30 |
| IV-04 Vanessa Baier PBPK model-guided assessment of a liver function test Thursday 15:00-16:30 |
| IV-05 Pavel Balazki PB-QSP model of type 2 diabetes for individualized prediction of treatment combination outcomes with metformin, DPP4i, and SGLT2i. Thursday 15:00-16:30 |
| IV-06 Sara Bettonte Cabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling Thursday 15:00-16:30 |
| IV-07 Dominic Bräm Opportunities of Covariate Data Imputation with Machine Learning for Pharmacometricians in R Thursday 15:00-16:30 |
| IV-08 Katherine Briceno Feedforward neural network as a surrogate for the reinforcement learning action-value function in a model-informed precision dosing oncology application Thursday 15:00-16:30 |
| IV-09 Núria Buil Bruna Can mAb dose selection in IBD be supported by public domain data from other immune-mediated inflammatory diseases? Thursday 15:00-16:30 |
| IV-10 Letizia Carrara Prospective predictions of drug pharmacokinetics and food effect in pediatrics via PBPK modelling Thursday 15:00-16:30 |
| IV-11 Simon Carter The development of artificial neural networks for the prediction of influential individuals and outlying individuals and their application during the model building process Thursday 15:00-16:30 |
| IV-12 Estelle Chasseloup Comparison of seven NLMEM approaches to test for drug effect using real placebo data Thursday 15:00-16:30 |
| IV-13 Marylore Chenel Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children Thursday 15:00-16:30 |
| IV-14 Suein Choi Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients Thursday 15:00-16:30 |
| IV-15 Suein Choi DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data Thursday 15:00-16:30 |
| IV-16 Pavlos Chrysafidis Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPK) models Thursday 15:00-16:30 |
| IV-17 Yumi Cleary Physiologically-based pharmacokinetic modelling of basmisanil to evaluate CYP3A mediated victim and perpetrator drug-drug interaction propensity Thursday 15:00-16:30 |
| IV-18 Emmanuelle Comets Conditional non-parametric bootstrap for non-linear mixed effect models Thursday 15:00-16:30 |
| IV-19 Marina Cuquerella Gilabert Towards PBPK model development for oral absorption in PhysPK Thursday 15:00-16:30 |
| IV-20 Alessandro De Carlo A Two-Stages Global Sensitivity Analysis in presence of correlated inputs: Application on a Tumor-in-host-growth Inhibition model based on the Dynamic Energy Budget theory Thursday 15:00-16:30 |
| IV-21 Thibaud Derippe Accelerating robust virtual patient (VP) population generation by substituting ODE solving with simple parameter comparisons Thursday 15:00-16:30 |
| IV-22 Paul Matthias Diderichsen Characterising the onset of response using public domain data and MBMA: application cases in Atopic Dermatitis and Psoriatic Arthritis Thursday 15:00-16:30 |
| IV-23 Dominic Tong Comparing full Bayesian estimation to maximum a posteriori (MAP) Bayesian estimation in three routine clinical care scenarios Thursday 15:00-16:30 |
| IV-24 Julie Dudasova Leveraging immunogenicity data and logistic regression for detection of covariate effects on vaccine efficacy Thursday 15:00-16:30 |
| IV-25 Jeroen Elassaiss-Schaap Mixing of variability in the log-domain with normal-domain variability components may lead to biased estimation Thursday 15:00-16:30 |
| IV-26 Nivea M. F. Voelkner Implementation of Estimation Step Refinements to Support Runtime Reduction for Model Building in NONMEM® 7 Thursday 15:00-16:30 |
| IV-27 Laura Fuhr Peeling the grapefruit – investigating the drug interaction potential of grapefruit juice as CYP3A4 inhibitor using physiologically-based pharmacokinetic modeling Thursday 15:00-16:30 |
| IV-28 Mohamed Gewily Parametric and Non-Parametric Methods in Clinical Decision Making- A Comparison of Bias and Precision using Real Clinical Data Thursday 15:00-16:30 |
| IV-29 Sungwoo Goo Explainable covariate screening method using Artificial Neural Network (ANN) for Non-linear Mixed Effect Modeling Thursday 15:00-16:30 |
| IV-30 Alzahra Hamdan Automatic Development of Pharmacokinetic Structural Models – Pharmpy Model Search Tool Thursday 15:00-16:30 |
| IV-31 Zhe Huang Comparison of PK models using normal and log-transformed scale data Thursday 15:00-16:30 |
| IV-32 Jasmine Hughes PKPDposterior: R package for structured full-Bayesian model-informed precision dosing Thursday 15:00-16:30 |
| IV-33 Itziar Irurzun Arana A Long-Short Term Memory Approach to Predicting Neutrophil Count in Patients Undergoing Drug Treatment Thursday 15:00-16:30 |
| IV-34 Martin Johnson Developing a reinforcement learning algorithm to determine an optimal dosing regimen for cancer treatment Thursday 15:00-16:30 |
| IV-35 Niclas Jonsson Efficient and relevant stepwise covariate model building for pharmacometrics Thursday 15:00-16:30 |
| IV-36 Christos Kaikousidis Implementation of non-linear mixed effects models in NONMEM described by fractional differential equations. Thursday 15:00-16:30 |
| IV-37 Wojciech Krzyzanski Pharmacodynamic age structured population model for cell trafficking Thursday 15:00-16:30 |
| IV-38 Chun Liu Comparison of performances of the open-source R package “nlmixr” vs. Monolix for population pharmacokinetics of continuous infusion meropenem in patients with onco-hematological malignancies Thursday 15:00-16:30 |
| IV-39 Helena Loer Dose Adaptations for Drug-Gene and Drug-Drug Interactions involving Clopidogrel – A Physiologically based Pharmacokinetic (PBPK) Modeling Approach Thursday 15:00-16:30 |
| IV-40 James Lu Neural Ordinary Differential Equations for Tumor Dynamics Modeling and Overall Survival Predictions Thursday 15:00-16:30 |
| IV-41 Julia Macente Application of Physiologically-Based Pharmacokinetics using Simcyp to predict the exposure to Valproic Acid in human milk and pediatrics Thursday 15:00-16:30 |
| IV-42 Fatima Zahra Marok Physiologically-based pharmacokinetic modeling of drug-drug interactions with ketoconazole and its metabolite deacetyl-ketoconazole Thursday 15:00-16:30 |
| IV-43 Uri Nahum Innovative Machine Learning Based Algorithm to Differentiate Between Diabetes Insipidus and Primary Polydipsia in Clinical Practice Thursday 15:00-16:30 |
| IV-44 Nina Nauwelaerts Physiologically-Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to Sildenafil and Bosentan: a contribution from the ConcePTION Project Thursday 15:00-16:30 |
| IV-45 Morgane PHILIPP Model-based bioequivalence approach: robustness to model misspecification for sparse pharmacokinetic bioequivalence studies Thursday 15:00-16:30 |
| IV-46 Fiona Plait Physiologically Based Pharmacokinetic Modeling of a CYP3A4-Mediated Drug-Drug Interaction: Prediction of Victim of Induction, not Inhibition, with a Moderate Fraction Metabolized by CYP3A4 Thursday 15:00-16:30 |
| IV-47 Alicja Puszkiel A minimal PBPK model for plasma and cerebrospinal fluid pharmacokinetics of trastuzumab in patients with leptomeningeal carcinomatosis Thursday 15:00-16:30 |
| IV-48 Javier Reig-López A Physiologically Based Pharmacokinetic Model for Open Acid and Lactone Forms of Atorvastatin and Its Two Metabolites Thursday 15:00-16:30 |
| IV-49 Davide Ronchi Facing the limits of the genetic algorithms for covariate selection Thursday 15:00-16:30 |
| IV-50 Mark Sale Comparison of Robustness and Efficiency of Four Machine Learning Algorithms for Identification of Optimal Population Pharmacokinetic Models Thursday 15:00-16:30 |
| IV-51 Ayatallah Saleh Elucidating the complex pharmacokinetics of voriconazole leveraging a middle-out approach Thursday 15:00-16:30 |
| IV-52 Morwarid Shahhossini Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock Thursday 15:00-16:30 |
| IV-53 Yesong Shin Population pharmacokinetic modelling for enterohepatic circulation of leflunomide in healthy Korean Thursday 15:00-16:30 |
| IV-54 Florian Simon Application of the Quantitative System Toxicology model of drug-induced liver injury DILIsym to evaluate the hepatotoxic potential of drugs in early development Thursday 15:00-16:30 |
| IV-55 Erik Sjögren A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework Thursday 15:00-16:30 |
| IV-56 Victoria Smith PKPDAI: Unlocking Pharmacokinetic Data from Tables with Natural Language Processing Thursday 15:00-16:30 |
| IV-57 Victor Sokolov Deciphering the mechanisms of drug effects on cardiovascular system through semi-mechanistic modeling of preclinical telemetry data: a validation study Thursday 15:00-16:30 |
| IV-58 Britta Steffens Assessment of sensitivity and specificity in the context of pharmacometrics-based decision support tools: application to hyperbilirubinemia in neonates Thursday 15:00-16:30 |
| IV-59 Vo Thanh Covariate Modelling and Bayesian Inference for Physiologically Based Pharmacokinetic Models Thursday 15:00-16:30 |
| IV-60 Franziska Thoma Simple and illustrative model to study Bayesian hierarchical modelling approaches for continued learning in model-informed precision dosing Thursday 15:00-16:30 |
| IV-61 Eunsol Yang Prediction of gastric pH-mediated drug exposure changes using physiologically based pharmacokinetic modeling: A case study of itraconazole Thursday 15:00-16:30 |
